PMID- 2002547
OWN - NLM
STAT- MEDLINE
DCOM- 19910417
LR  - 20200724
IS  - 0022-538X (Print)
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Linking)
VI  - 65
IP  - 4
DP  - 1991 Apr
TI  - Characterization of immunodominant epitopes of gag and pol gene-encoded proteins 
      of human T-cell lymphotropic virus type I.
PG  - 1870-6
AB  - A series of synthetic peptides derived from the corresponding regions of the gag, 
      pol, and env proteins of human T-cell lymphotropic virus types I (HTLV-I) and II 
      (HTLV-II) were used in an enzyme immunoassay to map the immunodominant epitopes 
      of HTLV. Serum specimens from 79 of 87 (91%) HTLV-I-infected patients reacted 
      with the synthetic peptide Gag-1a (amino acids [a.a.] 102 to 117) derived from 
      the C terminus of the p19gag protein of HTLV-I. Minimal cross-reactivity (11%) 
      was observed with serum specimens from HTLV-II-infected patients. Peptide Pol-3, 
      encoded by the pol region of HTLV-I (a.a. 487 to 502), reacted with serum 
      specimens from both HTLV-I- and HTLV-II-infected patients (94 and 86%, 
      respectively). The antibody levels to Pol-3 were significantly higher (P less 
      than 0.01) in patients with HTLV-I-associated myelopathy/tropical spastic 
      paraparesis than in either adult T-cell leukemia patients or HTLV-I-positive 
      asymptomatic carriers. None of the other peptides studied demonstrated 
      significant binding to serum specimens obtained from HTLV-I- or HTLV-II-infected 
      individuals. While Gag-1a did not react with serum specimens from normal 
      controls, Pol-3 demonstrated some reaction with specimens from seronegative 
      individuals (11.4%). The antibodies to Gag-1a and Pol-3 in serum specimens from 
      HTLV-I-infected patients could be specifically inhibited by the corresponding 
      synthetic peptides and by a crude HTLV-I antigen preparation, indicating that 
      these peptides mimic native epitopes present in HTLV-I proteins that are 
      recognized by serum antibodies from HTLV-I- and -II-infected individuals.
FAU - Lal, R B
AU  - Lal RB
AD  - Retrovirus Diseases Branch, Centers for Disease Control, Atlanta, Georgia 30333.
FAU - Rudolph, D L
AU  - Rudolph DL
FAU - Griffis, K P
AU  - Griffis KP
FAU - Kitamura, K
AU  - Kitamura K
FAU - Honda, M
AU  - Honda M
FAU - Coligan, J E
AU  - Coligan JE
FAU - Folks, T M
AU  - Folks TM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
RN  - 0 (Gene Products, env)
RN  - 0 (Gene Products, gag)
RN  - 0 (Gene Products, pol)
RN  - 0 (HTLV-I Antibodies)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Amino Acid Sequence
MH  - Binding, Competitive
MH  - Gene Products, env/biosynthesis/genetics
MH  - Gene Products, gag/biosynthesis/*genetics
MH  - Gene Products, pol/biosynthesis/*genetics
MH  - HTLV-I Antibodies/*biosynthesis
MH  - HTLV-I Infections/complications/immunology
MH  - Human T-lymphotropic virus 1/*genetics/immunology
MH  - Humans
MH  - Immunodominant Epitopes/*genetics
MH  - Immunoglobulin G/immunology
MH  - Molecular Sequence Data
MH  - Paraparesis, Tropical Spastic/complications/immunology
MH  - Protein Conformation
PMC - PMC239998
EDAT- 1991/04/01 00:00
MHDA- 1991/04/01 00:01
PMCR- 1991/04/01
CRDT- 1991/04/01 00:00
PHST- 1991/04/01 00:00 [pubmed]
PHST- 1991/04/01 00:01 [medline]
PHST- 1991/04/01 00:00 [entrez]
PHST- 1991/04/01 00:00 [pmc-release]
AID - 10.1128/JVI.65.4.1870-1876.1991 [doi]
PST - ppublish
SO  - J Virol. 1991 Apr;65(4):1870-6. doi: 10.1128/JVI.65.4.1870-1876.1991.